Cargando…

A case of HCC successfully treated with infliximab‐steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy

BACKGROUND: Although reports of gastrointestinal perforation after immune‐related adverse events (irAE) enteritis are rare, the anti‐ vascular endothelial growth factor (VEGF) effect of bevacizumab may be involved in gastrointestinal perforation. We report a rare case of gastrointestinal perforation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hagiwara, Satoru, Komeda, Yoriaki, Nishida, Naoshi, Yoshida, Akihiro, Kudo, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675378/ https://www.ncbi.nlm.nih.gov/pubmed/36224043 http://dx.doi.org/10.1002/cnr2.1721

Ejemplares similares

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis
por: Hagiwara, Satoru, et al.
Publicado: (2017)

Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma
por: Otsuka, Yasuo, et al.
Publicado: (2023)

Cases with Refractory Ascites and a Delayed Response to Tolvaptan
por: Hagiwara, Satoru, et al.
Publicado: (2016)

Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
por: Kudo, Masatoshi
Publicado: (2021)

Successful initial tofacitinib treatment for acute severe ulcerative colitis with steroid resistance: a case series
por: Komeda, Yoriaki, et al.
Publicado: (2023)

Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
por: Hagiwara, Satoru, et al.
Publicado: (2021)

Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response
por: Minami, Yasunori, et al.
Publicado: (2022)

Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Artificial intelligence-based endoscopic diagnosis of colorectal polyps using residual networks
por: Komeda, Yoriaki, et al.
Publicado: (2021)

Erythropoietic Protoporphyria-related Hepatopathy Successfully Treated with Phlebotomy
por: Yoshida, Akihiro, et al.
Publicado: (2018)

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
por: Joerg, Vincent, et al.
Publicado: (2023)

Corneal Perforation in a Patient Treated with Atezolizumab-Bevacizumab Combination Therapy for Unresectable Hepatocellular Carcinoma
por: Alkharashi, Majed S., et al.
Publicado: (2023)

Advances in Immunotherapy for Hepatocellular Carcinoma
por: Hagiwara, Satoru, et al.
Publicado: (2023)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Risk factors for local recurrence and appropriate surveillance interval after endoscopic resection
por: Komeda, Yoriaki, et al.
Publicado: (2019)

Castor oil as booster for colon capsule endoscopy preparation reduction: A prospective pilot study and patient questionnaire
por: Takashima, Kota, et al.
Publicado: (2021)

Atezolizumab and Bevacizumab Combination Therapy and Sequential Conversion Hepatectomy for Advanced Fibrolamellar Hepatocellular Carcinoma Presenting Pseudoprogression
por: Matsuki, Ryota, et al.
Publicado: (2022)

The oncoprotein gankyrin promotes the development of colitis-associated cancer through activation of STAT3
por: Sakurai, Toshiharu, et al.
Publicado: (2017)

Serum leucine‐rich alpha‐2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy‐naïve cases with ulcerative colitis
por: Kono, Masashi, et al.
Publicado: (2023)

Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis
por: Kono, Masashi, et al.
Publicado: (2019)

Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma
por: Yano, Yoshihiko, et al.
Publicado: (2023)

Case Report: Successful liver transplantation after achieving complete clinical remission of advanced HCC with Atezolizumab plus Bevacizumab combination therapy
por: Chouik, Yasmina, et al.
Publicado: (2023)

Dysbiosis-Associated Polyposis of the Colon—Cap Polyposis
por: Okamoto, Kazuki, et al.
Publicado: (2018)

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria
por: Hagiwara, Satoru, et al.
Publicado: (2022)

Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients
por: Kondo, Takayuki, et al.
Publicado: (2023)

Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease
por: Kono, Masashi, et al.
Publicado: (2019)

Purpura-free small intestinal IgA vasculitis complicated by cytomegalovirus reactivation
por: Matsumura, Mariko, et al.
Publicado: (2020)

Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
por: Kudo, Masatoshi, et al.
Publicado: (2023)

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment
por: Hosoda, Shunichi, et al.
Publicado: (2022)

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2023)

Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report
por: Komeda, Yoriaki, et al.
Publicado: (2020)

Usefulness of the Novel Snare-over-the-Guidewire Method for Transpapillary Plastic Stent Replacement (with Video)
por: Yoshida, Akihiro, et al.
Publicado: (2021)

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
por: Tella, Sri Harsha, et al.
Publicado: (2022)

The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Shimose, Shigeo, et al.
Publicado: (2023)

Endoscopic submucosal dissection with reinforcement using a laparoscopic approach for a duodenal cavernous hemangioma
por: Masaki, Sho, et al.
Publicado: (2022)

A case of small invasive gastric cancer arising from Helicobacter pylori‐negative gastric mucosa: Fundic gland‐type adenocarcinoma
por: Komeda, Yoriaki, et al.
Publicado: (2017)

Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma
por: Manzar, Gohar Shahwar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hp2arrse0keoa0pg0lkh96ff14